Mass Spec

News on mass spectrometry technology and applications in genetics, genomics, and molecular diagnostics.

The test measures the multiple myeloma marker M protein and could prove more sensitive and less susceptible to interferences than existing assays.

They acknowledge that while the technical hurdles of proteomic test development have become manageable, commercialization is still a major challenge.

The proteomics firm is swapping 4 million of its shares for a 10 percent interest in CPR with the goal of moving into clinical trials and related research.

Researchers found that 98 percent of the identifications the system provided were correct, indicating the usefulness of the platform in clinical mycology.

The recent study highlights strengths and weaknesses of numerous platforms and may help end users choose the best assay for their circumstances.